Teva Pharmaceutical Industries Ltd. (TEVA), Celltrion, Team Up To Market mAb Biosimilars

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) recently entered into an exclusive agreement with Celltrion, Inc. to commercialize P10 and CT-P6, the latter’s two monoclonal antibody (mAb) biosimilar candidates. The deal covers North America.

medication, pharmacist, shelf, care, pharmaceutical, medical, day, drug, clinic, medicament, drugstore, treatment, ill, smiling, medicine, pharmaceutics, of, hospital,

wavebreakmedia/Shutterstock.com

New Partnership

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will pay $160 million to Celltrion in an upfront payment. A maximum $60 million of the upfront payment is refundable under certain circumstances. Both companies will share the resulting revenues in North America. John Carroll, a biotech analyst, tweeted the following yesterday on the deal: